Retinset

What Retinset does

Retinset, S.L. is a clinical-stage Spanish biotechnology company headquartered in Sant Cugat del Vallès (Barcelona metropolitan area), structured as a private limited company (RETINSET, S.L., Tax ID B66403064). It operates as a spin-out from Medical Mix, which remains its strategic parent and source of foundational ophthalmic and retinal-pathology expertise.

The company's core product is BSL01, a first-in-class topical ophthalmic formulation (eye drops) designed to deliver drugs to the retina — historically a major unsolved problem in ocular therapeutics. BSL01 is positioned for the prevention and treatment of early-stage Diabetic Retinopathy (DR), providing dual-action neuroprotection and microvascular protection and targeting a population the company estimates at 144 million patients worldwide. The underlying platform — an eco-friendly, patent-protected formulation strategy — constitutes the company's principal technological asset, and Retinset has successfully completed a Phase I Clinical Trial for BSL01.

Retinset is pre-revenue with no commercial product, no disclosed pricing model, and no announced equity funding rounds. Public/non-dilutive support comes from Spanish institutional backers including CDTI, the European Commission (Seal of Excellence), the Spanish Patent and Trademark Office (OEPM), and the Spanish State Secretariat for Research, Development and Innovation. The company maintains a corporate website and LinkedIn presence as its primary channels; future commercialization will likely require pharmaceutical partnerships, licensing agreements, or direct sales infrastructure post-regulatory approval, but no such commercial GTM is yet in place.

Name

Retinset

Legal name

RETINSET, S.L.

Website

https://retinset.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Retinset is a clinical-stage Spanish biotech spin-out from Medical Mix developing BSL01, a first-in-class topical eye-drop formulation that delivers drugs to the retina to prevent and treat early-stage Diabetic Retinopathy, having completed Phase I trials.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Ophthalmic drug delivery
• Diabetic retinopathy treatment
• Retinal therapeutics
• Topical ophthalmic formulations
• Biopharmaceutical drug development

Headquarters

HQ city

Sant Cugat Del Vallès

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Marketing channels2 records

Core offering

Retinset is a clinical-stage biopharmaceutical company developing BSL01, a first-in-class topical ophthalmic eye drop formulation intended to prevent and treat early-stage Diabetic Retinopathy. The product leverages a proprietary drug delivery platform that enables therapeutics to effectively reach the retina via non-invasive eye drops, offering dual neuroprotection and microvascular protection. Retinset has successfully completed Phase I Clinical Trials for BSL01 and is advancing the program toward further clinical development.

Product overview

Retinset is a clinical-stage biotech company providing ophthalmic therapeutics through a single core product. Their lead product BSL01 is a first-in-class eye drop formulation for Diabetic Retinopathy that represents an innovative drug delivery platform enabling topical ophthalmic medications to effectively reach the retina. The company has completed Phase I Clinical Trials and is advancing its portfolio toward further clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• BSL01 BSL01 is a first-in-class topical ophthalmic formulation (eye drops) designed to prevent and regress early-stage Diabetic Retinopathy. It enables drugs to effectively reach the retina via an innovative delivery solution, providing dual-action neuroprotection and microvascular protection to halt disease progression and revert effects. The product targets working-aged adults with early-stage Diabetic Retinopathy and the ophthalmologists who treat them.

Quantifiable outcome

• Phase I Clinical Trial successfully completed
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Medical MixcoreStrategic or Co-development PartnerParent company from which Retinset spun out as a clinical-stage company. Medical Mix provides the foundational expertise and infrastructure for retinal pathology treatments and drug delivery solutions.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Outlook Therapeutics: Outlook Therapeutics is developing ONS-5010 / LYTENAVA (bevacizumab), an ophthalmic formulation for wet AMD and related retinal vascular conditions. It is an emerging player peer because both companies are clinical-stage firms developing novel ophthalmic formulations targeting retinal disease.
• Aerpio Pharmaceuticals: Aerpio developed small-molecule therapeutics targeting vascular endothelial dysfunction for diabetic eye disease, including AKB-9778 for diabetic retinopathy. It is an emerging player peer because both Retinset and Aerpio focused on non-anti-VEGF mechanisms to address early-stage diabetic retinal disease.

Direct peers

• Clearside Biomedical: Clearside Biomedical has built a proprietary suprachoroidal drug delivery platform (Xipere) for retinal diseases including macular edema associated with uveitis and diabetic retinopathy. It is a direct peer because both firms aim to overcome the limits of topical and intravitreal delivery to treat retinal disease more effectively.
• Ocular Therapeutix: Ocular Therapeutix develops proprietary ocular drug delivery platforms including hydrogel-based eye drops and implants for retinal and anterior segment diseases. It is a direct peer because Retinset's BSL01 also leverages a novel ocular formulation to deliver therapeutic agents to back-of-the-eye targets via eye drops.
• EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery technologies (Durasert, bioerodible implants) for retinal diseases including diabetic retinopathy and DME. It is a direct peer because both companies are focused on novel delivery solutions that target retinal pathologies from outside conventional anti-VEGF injections.
• Aerie Pharmaceuticals: Aerie Pharmaceuticals developed innovative ophthalmic therapies for glaucoma and other eye diseases using novel small-molecule formulations and was acquired by Alcon. It is a direct peer in ophthalmic drug delivery/formulation innovation, though focused more on anterior segment than retinal indications.
• Kodiak Sciences: Kodiak Sciences develops novel biologics (e.g., KSI-301 / tarcocimab) for retinal vascular diseases including diabetic retinopathy, diabetic macular edema, and wet AMD. It is a direct peer because both companies pursue improved therapeutics for DR, albeit via different modalities (ocular delivery platform vs. antibody biopolymer conjugate).

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron co-developed Eylea (aflibercept), the leading anti-VEGF therapy for diabetic retinopathy and DME. It is a broad incumbent because any new DR therapy from Retinset must compete against or position relative to Regeneron's entrenched Eylea franchise in retinal vascular disease.
• Roche / Genentech: Roche/Genentech markets Lucentis (ranibizumab) and develops additional ophthalmic therapeutics for retinal vascular disease including DR. It is a broad incumbent because Retinset's target indication is directly addressed by Roche's existing anti-VEGF franchise.
• Alcon: Alcon is the world's largest dedicated eye-care company with a broad ophthalmic pharmaceutical and surgical portfolio including treatments for retinal disease. It is a broad incumbent because Retinset's BSL01, if successful, would compete within Alcon's ophthalmic franchise and Alcon is also a likely strategic acquirer of novel retinal delivery platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/retinset

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retinset